Trade AstraZeneca ^AZN

AstraZeneca PLC (LON:AZN) Insider Tony Mok Buys 1,500 Shares

astrazeneca non-executive director buys company shares By Investing.com

Howe & Rusling Inc. Sells 29,784 Shares of AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca (NASDAQ:AZN) Upgraded at UBS Group | MarketBeat

Jennison Associates LLC Sells 2,059,108 Shares of AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca shares trade higher on UBS Upgrade By Investing.com

Leerink Partnrs Predicts Increased Earnings for AstraZeneca

AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades

AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Boosted by Pathstone Holdings LLC

Leerink Partnrs Reduces Earnings Estimates for AstraZeneca

Can AstraZeneca stock recover? UBS points to regulatory support despite challenges By Investing.com

New Millennium Group LLC Sells 28,749 Shares of AstraZeneca PLC (NASDAQ:AZN)

Prospera Financial Services Inc Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Leerink Partnrs Cuts Earnings Estimates for AstraZeneca

SouthState Corp Acquires 1,025 Shares of AstraZeneca PLC (NASDAQ:AZN)

Jones Trading raises Monopar Therapeutics target to $37 By Investing.com

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Sumitomo Mitsui Trust Group Inc.

Analysts Set AstraZeneca PLC (LON:AZN) PT at £104.12

Stocks in news: Waaree Energies, GMR Infra, AstraZeneca, Indus Towers, Ashoka Buildcon & ITI

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC - November 19, 2024 - Zacks.com

Daiichi Sankyo, Astrazeneca submit new BLA for Trop2 lung cancer ADC | BioWorld

Regulatory actions for Nov. 19, 2024 | BioWorld

Lunit Collaborates With AstraZeneca To Develop AI-powered Digital Pathology Solutions | Markets Insider

AstraZeneca to launch Breztri Aerosphere for COPD treatment following DCGI approval, ET LegalWorld

Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC | The Manila Times

Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now?

EMA committee recommends approval of AstraZeneca’s lung-cancer drug ‘Tagrisso’

Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now?

Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program | The Manila Times

Political Shifts: The Pulse of Pharma Stock Volatility

Trump’s Nomination of RFK Jr. to Lead HHS a Potential Industry Headwind | Morningstar

Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - November 18, 2024 - Zacks.com

Astrazeneca exercises option for type 1 diabetes Treg cell therapy program with Quell | BioWorld

Other news to note for November 18, 2024 | BioWorld

Pascal Soriot Purchases 20,000 Shares of AstraZeneca PLC (LON:AZN) Stock

Natixis Advisors LLC Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN)

AIM ImmunoTech Inc. (AMEX:AIM) Q3 2024 Earnings Call Transcript - Insider Monkey

AstraZeneca PLC (NASDAQ:AZN) Sees Large Increase in Short Interest

AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Koa Wealth Management LLC

Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK By Proactive Investors

Insider Buying: AstraZeneca PLC (LON:AZN) Insider Buys 20,000 Shares of Stock

Sustainability consultancy eyes growth following £500k backing | TheBusinessDesk.com

AstraZeneca (NASDAQ:AZN) Releases Earnings Results, Beats Estimates By $0.03 EPS

FTSE 100 subdued as pharma stocks weigh By Reuters

Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback - November 15, 2024 - Zacks.com

AstraZeneca (NASDAQ:AZN) Announces Earnings Results

AstraZeneca (NASDAQ:AZN) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

AstraZeneca slumps as Q2 PAT slides 27% YoY to Rs 38 cr | Capital Market News - Business Standard

Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline By Investing.com

LBT Innovations Rebrands and Expands in Pharma Market

Kepler Capital Remains a Hold on AstraZeneca (AZN)

MQS Management LLC Has $832,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Absci Corporation (NASDAQ:ABSI) Q3 2024 Earnings Call Transcript

AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call Transcript

Healthy Returns: AstraZeneca boosts U.S. investment on confidence in economy

AstraZeneca's (AZN) Robust Growth in China Despite Leadership Challenges

AstraZeneca Pharma India Q2FY25 results: Net profit falls 27% to Rs 38 cr | Company Results - Business Standard

AstraZeneca Investment: AstraZeneca announces $3.5 billion plan to expand U.S. R&D and manufacturing operations, ETPharma

AstraZeneca Q2 net profit declines 10%, revenue up 31%

CWA Asset Management Group LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

AstraZeneca Reports Strong Growth in Q3 2024

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results By Investing.com

Trending: AstraZeneca Expands Its Investment Plan in the U.S. | Morningstar

AstraZeneca Talks Up US Growth as China Problems Worsen

AstraZeneca lifts outlook as it doubles down on US growth

AstraZeneca invests $3.5 billion in US expansion By Investing.com

Wuxi's iCampus signs strategic cooperation with HK's health center and AstraZeneca - Chinadaily.com.cn

AstraZeneca PLC (NASDAQ:AZN) Given Consensus Recommendation of “Buy” by Analysts

AstraZeneca says it’s taking China’s investigations into fraud, illegal drug importation and data collection ‘very seriously’

Astra Invests $3.5 Billion in US as Cancer Drug Lifts Sales

AstraZeneca raises expectation for next year profits after Q3 performance | World News - Business Standard

City round-up; Franchise Brands; BAE Systems; Coral Products; Astra Zeneca; Convatec; McBride | TheBusinessDesk.com

AstraZeneca's 9M and Q3 2024 results By Investing.com

AstraZeneca To Invest $3.5 Bln In US To Expand R&D And Manufacturing | Markets Insider

AstraZeneca Raises Outlook on Earnings, Sales Beat | Morningstar

AstraZeneca Q3 Net Income Rises; Upgrades 2024 Guidance

CREDIT UPDATE: AstraZeneca (AZN: A2 pos/A+/Au pos): 3Q24

AstraZeneca: Koselugo Phase III Trial Meets Primary Goal In Adults With Neurofibromatosis Type 1

AstraZeneca Q3 earnings beat estimates, raises full-year outlook By Investing.com

European markets fall as mining stocks slide; Bayer shares at 20-year lows; Mediobanca down 8%

AstraZeneca raises 2024 outlook on strong Q3 By Investing.com

AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat By Reuters

AstraZeneca investing $3.5bn in R & D and manufacturing in the US

AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US - November 12, 2024 - Zacks.com

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer By Investing.com

AstraZeneca News | Markets Insider

Biliary Tract Cancer Market Size in the 7MM was ~USD 1000 million, is expected to grow by 2034, estimated DelveInsight

GDS Wealth Management Sells 448 Shares of AstraZeneca PLC (NASDAQ:AZN)

Buckingham Capital Management Inc. Sells 10,133 Shares of AstraZeneca PLC (NASDAQ:AZN)

Earnings To Watch: AstraZeneca PLC (OSTO:AZN) Reports Q3 2024 Result

Atria Investments Inc Buys 9,431 Shares of AstraZeneca PLC (NASDAQ:AZN)

ANGLE plc ("the Company") DNA ANALYSIS OF PARSORTIX-ENRICHE